Vincristine-induced neurotoxicity in pediatric patients with rhabdomyosarcoma: A retrospective analysis of clinical features and outcome
Loading...
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Taylor and Francis Ltd.
Abstract
Vincristine is an essential component of rhabdomyosarcoma treatment. However, it can cause motor neurotoxicity, necessitating dose reductions. We retrospectively reviewed the rates and patterns of vincristine-induced motor neuropathy in children treated for rhabdomyosarcoma, and investigated effects on outcome. Fifteen of 43 patients (35%) developed motor neuropathies necessitating dose reductions, which ranged from 1.7% to 58% of planned cumulative dose. Older age was the only significant clinical risk factor. Almost half (47%) recovered during treatment with subsequent dose escalation. Most patients had complete resolution of symptoms upon follow-up. There was no discernible effect of treatment reduction on survival or relapse rates. © 2022 Taylor & Francis Group, LLC.
Description
Keywords
Neuropathy, Neurotoxicity, Rhabdomyosarcoma, Vincristine, Antineoplastic combined chemotherapy protocols, Child, Humans, Neoplasm recurrence, local, Neurotoxicity syndromes, Retrospective studies, Rhabdomyosarcoma, embryonal, Antineoplastic agent, Adolescent, Arm weakness, Article, Clinical article, Clinical feature, Clinical outcome, Controlled study, Disease duration, Disease exacerbation, Disease severity, Drug dose escalation, Drug dose reduction, Drug substitution, Drug withdrawal, Event free survival, Female, Follow up, High risk patient, Hoarseness, Human, Infant, Intermediate risk patient, Low risk patient, Male, Muscle weakness, Neurologic gait disorder, Overall survival, Peripheral neuropathy, Peroneus nerve paralysis, Ptosis (eyelid), Recurrence risk, Recurrent disease, Relapse, Remission, Retrospective study, Risk factor, Senescence, Sensory neuropathy, Complication, Drug therapy, Embryonal rhabdomyosarcoma, Toxicity and intoxication, Tumor recurrence